Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy

Clinical and Experimental Immunology

Volumn 109, Issue 1, 1997, Pages 32-40

  Rutjes, S A ^a   Vree Egberts, W T M ^a   Jongen, P ^b   Van Den Hoogen, F ^b   Pruijn, G J M ^a   Van Venrooij, W J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Complex; Jo 1; Myositis autoantibodies; Ro (SS A); Ro ribonucleoprotein

Indexed keywords

AUTOANTIBODY; EPITOPE; RECOMBINANT PROTEIN; RIBONUCLEOPROTEIN;

ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IDIOPATHIC DISEASE; IMMUNOPRECIPITATION; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; SERUM;

EID: 8544276567     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4081308.x     Document Type: Article

References (50)

1. Plotz PH, Rider LG, Targoff IN, Rahen N, O'Hanlon TP, Miller FW. NIH conference. Myositis: immunologic contributions to understnading cause, pathogenesis, and therapy. Ann Intern Med 1995; 122:715-24.
2. Joffe MM, Love LA, Leff RL et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94:379-87.
3. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine Baltimore 1991; 70:360-74.
4. Tan EM. Antinuclear antibodies: diagnostic markers for atuoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93-151.
5. Mirande M. Aminoacyl-tRNA synthetase family from prokaryotes and eukaryotes: structural domains and their implications. Prog Nucleic Acid Res Mol Biol 1991; 40:95-142.
6. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983; 304:177-9.
7. Mathews MB, Reichlin M, Hughes GR, Bernstein RM. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984; 160:420-34.
8. Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986; 163:1281-91.
9. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990; 144:1737-43.
10. Craft J, Hardin JA. Antinuclear antibodies. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology, 4th edn. 1993; 164-87.
11. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985; 28:796-803.
12. Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995; 38:1389-99.
13. Hendrick JP, Wolin SL, Rinke J, Lerner MR, Steitz JA. Ro small cytoplasmic ribonucleoproteines are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. Mol Cell Biol 1981; 1:1138-49.
14. Gottlieb E, Steitz JA. The RNA binding protein La influences both the accuracy and the efficiency of RNA polymerase III transcription in vitro. EMBO J 1989; 8:841-50.
15. Gottlieb E, Steitz JA. Function of the mammalian La protein: evidence for its action in transcription termination by RNA polymerase III. EMBO J 1989; 8:851-61.
16. Wolin SL, Steitz JA. The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs. Proc Natl Acad Sci USA 1984; 81:1996-2000.
17. Pruijn GJ, Slobbe RL, Van Venrooij WJ. Analysis of protein-RNA interactions within Ro ribonucleoprotein complexes. Nucleic Acids Res 1991; 19:5173-80.
18. Boire G, Gendron M, Monast N, Bastin B, Menard HA. Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD protein is not a Ro protein. Clin Exp Immunol 1995; 100:489-98.
19. Kelekar A, Saitta MR, Keene JD. Molecular composition of Ro small ribonucleoprotein complexes in human cells. Intracellular localization of the 60- and 52-kD proteins. J Clin Invest 1994; 93:1637-44.
20. Slobbe RL, Pluk W, Van Venrooij WJ, Pruijn GJ. Ro ribonucleoprotein assembly in vitro. Identification of RNA-protein and protein-protein interactions. J Mol Biol 1992; 227:361-6.
21. Peek R, Pruijn GJM, Van Venrooij WJ. Epitope specificity determines the ability of anti-Ro52 autoantibodies to precipitate Ro ribonucleoprotein particles. J Immunol 1994; 153:4321-9.
22. Peek R, Pruijn GJ, Van der Kemp, AJ, Van Venrooij WJ. Subcellular distribution of Ro ribonucleoprotein complexes and their constituents. J Cell Sci 1993; 106:929-35.
23. Ben Chetrit E, Chan EK, Sullivan KF, Tan EM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med 1988; 167:1560-71.
24. Slobbe RL, Pruijn GJ, Damen WG, van der Kemp JW, Van Venrooij WJ. Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins [published erratum appears in Clin Exp Immunol 1992; 87:336]. Clin Exp Immunol 1991; 86:99-105.
25. Itoh Y, Itoh K, Frank MB, Reichlin M. Autoantibodies to the Ro/SSA autoantigen are conformation dependenl-II - Antibodies to the denatured form of 52-kD Ro/SSA are a cross reacting subset of antibodies to the native 60-kD Ro/SSA molecule. Autoimmunity 1992; 14:89-95.
26. Bohan A, James JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56:225-86.
27. de Rooij DJ, van de Putte LB, Habets WJ, Verbeek AL, Van Venrooij WJ. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic dieases. Scand J Rheumatol 1988; 17:353-64.
28. Raben N, Borriello F, Amin J, Horwitz R, Fraser D, Plotz P. Human histidyl-tRNA synthetase: recognition of amino acid signature regions in class 2a aminoacyl-tRNA synthetases. Nucleic Acids Res 1993; 20:1075-81.
29. Misaki Y, Van Venrooij WJ, Pruijn GJ. Prevalence and characteristics of anti-56K/annexin XI autoantibodies in systemic autoimmune diseases. J Rheumatol 1995; 22:97-102.
30. Božič B, Pruijn GJM, Rozman B, Van Venrooij WJ. Sera from patients with rheumatic diseases recognize different epitope regions on the 52-kD Ro/SS-A protine. Clin Exp Immunol 1993; 94:227-35.
31. Chan EKL, Didonato F, Hamel JC, Tseng CE, Buyon JP. 52-kD SS-A/Ro: genomic structure and identification of an alternatively spliced transcript encoding a novel leucine zipper-minus autoantigen expressed in fetal and adult heart. J Exp Med 1995; 182:983-92.
32. Scherly D, Boelens W, Van Venrooij WJ, Dathan NA, Hamm J, Mattaj IW. Identification of the RNA binding segment of human U1 A protein and definition of its binding site on U1 snRNA. EMBO J 1989; 8:4163-70.
33. Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of protiens in the range from 1 to 100kDa, Anal Biochem 1987; 166:368-79.
34. Zieve G, Fury M, Jansen EJ. Analysis of autoimmune sera by immunoprecipitation of cellular RNPs. In: van Venrooij WJ, Maini RN, eds. Manual of biological markers of disease. Dordrecht: Kluwer Academic Publishers, 1993.
35. Olmsted JB. Affinity purification of antibodies from diazotized paper blots of heterogeneous samples. J Biol Chem 1981; 256: 11955-7.
36. Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994; 10:857-80.
37. Marguerie C, Bunn CC, Beynon HL et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77:1019-38.
38. Manoussakis MN, Tzioufas AG, Pange PJ, Moutsopoulos HM. Serological profiles in subgroups of patients with Sjögren's syndrome. Scand J Rheumatol Suppl 1986; 61:89-92.
39. Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36:340-7.
40. Andonopoulos AP, Skopouli FN, Dimou GS, Drosos AA, Moutsopoulos HM. Sjögren's syndrome in systemic lupus erythematosus. J Rheumatol 1990; 17:201-4.
41. Vlachoyiannopoulos PG, Zerva LV, Skopouli FN, Drosos AA, Moutsopoulos HM. D-penicillamine toxicity in Greek patients with rheumatoid arthritis: anti-Ro(SSA) antibodies and cryoglobulinemia are predictive factors. J Rheumatol 1991; 18:44-49.
42. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block-outcome in mothers and children. Ann Intern Med 1994; 120:544-51.
43. Alber T. Structure of the leucine zipper. Curr Opin Genet Dev 1992; 2:205-10.
44. Frank MB, Itoh K, Mccubbin VR. Epitope mapping of the 52-kD Ro/ SSA autoantigen. Clin Exp Immunol 1994; 95:390-6.
45. Buyon JP, Slade SG, Reveille JD, Hamel JC, Chan EKL. Autoantibody responses to the native 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjögrens syndrome. J Immunol 1994; 152:3675-84.
46. Ricchiuti V, Briand JP, Meyer O, Isenberg DA, Pruijn G, Muller S. Epitope mapping with synthetic peptides of 52-kD SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera. Clin Exp Immunol 1994; 95:397-407.
47. Dorner T, Feist E, Wagenmann A et al. Anti-52 kDa Ro(SSA) autoantibodies in different autoimmune disease preferentially recognize epitopes on the central region of the antigen. J Rheumatol 1996; 23:462-8.
48. McCauliffe DP, Yin H, Wang LX, Lucas L. Autoimmune sera react with multiple epitopes on recombinant 52 and 60kDa Ro(SSA) proteins. J Rheumatol 1994; 21:1073-80.
49. Blange I, Ringertz NR, Petterson I. Identification of antigenic regions of the human 52 kD Ro/SS-A protein recognized by patient sera. J Autoimmun 1994; 7:263-74.
50. Kato T, Sasakawa H, Suzuki S et al. Autoepitopes of the 52-kD SS-A/Ro molecule. Arthritis Rheum 1995; 38:990-8.